Cite
MLA Citation
B C Cho et al.. “1275PSafety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC).” Annals of oncology, vol. 30, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100097084058.0x000022